Developing Safe Oncolytic Virus Therapies
Ixogen Ltd is a UK based Biotechnology company focused on the research, development and
commercialisation of safe and effective oncolytic viruses for the treatment of cancer
Established in 2011, Ixogen is a privately-owned UK Biotechnology Research and Development company focused on the development of new therapeutic approaches for tumours that currently lack effective treatment.
The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumour cells for the treatment of cancer.
Ixogen’s technology promises alternatives for the treatment of solid tumours such as head and neck squamous cell carcinoma (HNSCC), pancreatic and colorectal cancer. Ixogen’s lead product is Ixovex-1.
